FASEB J. Pierce now sold as Thermo Scientific
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Taylor, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taylor, D. P.

The FASEB Journal, Vol 2, 2445-2452, Copyright © 1988 by The Federation of American Societies for Experimental Biology

REVIEWS

Buspirone, a new approach to the treatment of anxiety

DP Taylor
CNS Biology, Pharmaceutical Research and Development Division, Bristol- Myers Company, Wallingford, Connecticut 06492.

Anxiety has historically been treated by agents with a sedative component to their action. In the last decade or so it has been determined that gamma-aminobutyric acid (GABA) receptors may mediate the anxiolytic actions of the benzodiazepines, propanediol carbamates, barbiturates, and ethanol. However, inasmuch as these drugs have additional pharmacological properties (sedation, muscle relaxation, seizure control), the search for an anxioselective drug was continued. Buspirone appears to be such a drug. Clinical studies have clearly demonstrated the efficacy of buspirone in the treatment of generalized anxiety disorder without the ancillary pharmacology of earlier anxiolytics. Buspirone does not act on the GABA receptor. Rather, its most salient interaction with neurotransmitter receptors occurs at the 5-HT1A serotonin receptor. This action is supported by studies focused on receptor binding, anatomical localization, biochemistry, neurophysiology, and animal behavior. The recognition that action at 5- HT1A receptors may be a viable approach to the pharmacotherapy of anxiety is evidenced by the number of other agents of this class under development by a number of pharmaceutical companies.


This article has been cited by other articles:


Home page
 J. Neurosci.Home page
Y. D. Teng, M. Bingaman, A. M. Taveira-DaSilva, P. P. Pace, R. A. Gillis, and J. R. Wrathall
Serotonin 1A Receptor Agonists Reverse Respiratory Abnormalities in Spinal Cord-Injured Rats
J. Neurosci., May 15, 2003; 23(10): 4182 - 4189.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
N. Sahibzada, M. Ferreira, A. M. Wasserman, A. M. Taveira-DaSilva, and R. A. Gillis
Reversal of Morphine-Induced Apnea in the Anesthetized Rat by Drugs that Activate 5-Hydroxytryptamine1A Receptors
J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 704 - 713.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. J. Winsauer, F. H. Rodriguez, A. E. Cha, and J. M. Moerschbaecher
Full and Partial 5-HT1A Receptor Agonists Disrupt Learning and Performance in Rats
J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 335 - 347.
[Abstract] [Full Text]

Home page
 J PsychopharmacolHome page
C. Pantelis and T. R. E. Barnes
Acute exacerbation of psychosis with buspirone?
J Psychopharmacol, January 1, 1993; 7(3): 295 - 300.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by The Federation of American Societies for Experimental Biology.